- Home
- ICCM vs CURX Comparison
ICCM vs CURX Comparison
Compare ICCM & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | CURX |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 9.4M |
| IPO Year | 2013 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ICCM | CURX |
|---|---|---|
| Price | $1.63 | $5.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 86.1K | 23.1K |
| Earning Date | 05-27-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $139.51 | N/A |
| Revenue Next Year | $75.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.18 |
| 52 Week High | $9.54 | $6.80 |
Technical Indicators
Market Signals| Indicator | ICCM | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 22.40 | 67.84 |
| Support Level | $0.22 | $3.91 |
| Resistance Level | $2.50 | $6.00 |
| Average True Range (ATR) | 0.16 | 0.48 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 4.71 | 82.67 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.